Oncolytic viruses: the power of directed evolution.
作者： Maxine Bauzon , Terry W. Hermiston
DOI: 10.1155/2012/586389
关键词:
摘要: Attempts at developing oncolytic viruses have been primarily based on rational design. However, this approach has met with limited success. An alternative employs directed evolution as a means of producing highly selective and potent anticancer viruses. In method, diverse are grown under conditions that maximize diversity then passaged meant to mimic those encountered in the human cancer microenvironment. Viruses which evolve thrive pressure isolated tested identify increased potency (i.e., ability replicate spread) and/or an therapeutic window differentiated replication spread tumor versus normal cells), both potential value but latter defines virus. Using ColoAd1, virus derived by prototype, we highlight benefits evolution, discuss methods “arm” these novel viruses, introduce techniques for their genetic modulation control.
hindawi.com参考文章(37)
Stéphanie Mundweiler, Marc Bierings, Danielle Thouvenot, Florence Morfin, Aloys C M Kroes, David Carrington, Petr Sedlacek, Delphine Falcon, Sophie Dupuis-Girod, Petr Cetkovsky, Maaoorten J D van Tol, In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antiviral Therapy. ,vol. 10, pp. 225- 229 ,(2005)
Lin Yang, Juan Li, Xiao Xiao, Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy. Methods of Molecular Biology. ,vol. 709, pp. 127- 139 ,(2011) , 10.1007/978-1-61737-982-6_8
Terry W Hermiston, Irene Kuhn, Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes Cancer Gene Therapy. ,vol. 9, pp. 1022- 1035 ,(2002) , 10.1038/SJ.CGT.7700542
Tony Reid, Robert Warren, David Kirn, Intravascular adenoviral agents in cancer patients: Lessons from clinical trials Cancer Gene Therapy. ,vol. 9, pp. 979- 986 ,(2002) , 10.1038/SJ.CGT.7700539
Anuj Gaggar, Dmitry M Shayakhmetov, André Lieber, CD46 is a cellular receptor for group B adenoviruses Nature Medicine. ,vol. 9, pp. 1408- 1412 ,(2003) , 10.1038/NM952
L. Lenaerts, L. Naesens, Antiviral therapy for adenovirus infections Antiviral Research. ,vol. 71, pp. 172- 180 ,(2006) , 10.1016/J.ANTIVIRAL.2006.04.007
J ZWIEBEL, Cancer gene and oncolytic virus therapy. Seminars in Oncology. ,vol. 28, pp. 336- 343 ,(2001) , 10.1016/S0093-7754(01)90128-9
M Bauzon, F Jin, P Kretschmer, T Hermiston, In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer Gene Therapy. ,vol. 16, pp. 1169- 1174 ,(2009) , 10.1038/GT.2009.69
Per Ljungman, Viral infections: current diagnosis and treatment. Hematology Journal. ,vol. 5, ,(2004) , 10.1038/SJ.THJ.6200425
Oliver Wildner, Dennis Hoffmann, Christian Jogler, Klaus Überla, Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Therapy. ,vol. 10, pp. 791- 802 ,(2003) , 10.1038/SJ.CGT.7700638